Gyre Therapeutics
GYRE
35 hedge funds and large institutions have $39.7M invested in Gyre Therapeutics in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
800% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 2
488% more capital invested
Capital invested by funds: $6.75M → $39.7M (+$32.9M)
84% more funds holding
Funds holding: 19 → 35 (+16)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
2.53% more ownership
Funds ownership: 4.13% → 6.66% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.06M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$2.72M |
| 3 |
NC
Nexthera Capital
New York
|
+$2.12M |
| 4 |
VMI
VHCP Management II
New York
|
+$1.6M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$847K |
Top Sellers
| 1 |
SCM
Sio Capital Management
New York
|
-$1.49M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$220K |
| 3 |
FPF
FNY Partners Fund
New York
|
-$25K |
| 4 |
FMA
FNY Managed Accounts
New York
|
-$2K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $5K | +$2.04K | +40 | +1,000% |
|
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | -$1.38K | -27 | -57% |
|
|
TDC
28
Thompson Davis & Co
Richmond,
Virginia
| $2K | +$867 | +17 | New |
|
|
IP
29
Intellectus Partners
San Francisco,
California
| $1K | – | – | – |
|
|
PAM
30
Panagora Asset Management
Boston,
Massachusetts
| $1K | – | – | – |
|
|
NMC
31
NEA Management Company
Timonium,
Maryland
| – | -$220K | -5,799 | Closed |
|
|
FMA
32
FNY Managed Accounts
New York
| – | -$2K | -53 | Closed |
|
33
Group One Trading
Chicago,
Illinois
| – | +$51 | +1 | New |
|
|
WCAMG
34
Woodard & Company Asset Management Group
Bermuda Run,
North Carolina
| – | +$51 | +1 | New |
|
GYRE Hedge Fund Activity: Q4 2017 in Review
35 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2017, worth a combined $39.7M — up 488% from $6.75M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GYRE positions and 2 closed out — a net gain of 16 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $3.06M. The largest seller was Sio Capital Management, cutting an estimated $1.49M.
- 35 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2017, up from 19 in Q3 2017.
- Funds reported $39.7M of Gyre Therapeutics stock for Q4 2017, up 488% quarter-over-quarter.
- 18 funds opened new Gyre Therapeutics positions in Q4 2017 and 2 closed out, a net change of +16 holders.
- The largest Gyre Therapeutics buyer in Q4 2017 was Acuta Capital Partners, an estimated $3.06M added.
- The largest Gyre Therapeutics seller in Q4 2017 was Sio Capital Management, an estimated $1.49M sold.
Based on aggregated 13F filings for Q4 2017.